Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla® Agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic...

US FDA Grants Mexiletine Orphan Drug Designation US FDA Grants Mexiletine Orphan Drug Designation Zug, Switzerland, 8 June 2019: Lupin is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD)...